Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | KCNN4 | O15554 | 2/20 | 0.32 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 2/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | BCDIN3D | Q7Z5W3 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5147620 | 0.87 | KIF11 (0.36) | ACSS2KDM4EKCNN4BCDIN3DBRD4 | |
| SCHEMBL5150635 | 0.83 | HDAC6 (0.38) | ACSS2ELANEGAA | |
| SCHEMBL5148585 | 0.82 | MEN1 (0.38) | MEN1KMT2A | |
| SCHEMBL5148605 | 0.79 | SIGMAR1 (0.43) | CNR2MEN1KMT2AGAA | |
| SCHEMBL5148558 | 0.79 | MEN1 (0.33) | MEN1KMT2A | |
| SCHEMBL5148601 | 0.78 | MTNR1B (0.39) | LPAR1GAA | |
| SCHEMBL5147593 | 0.77 | CYP4F2 (0.48) | POLBKDM4EMEN1KMT2AGAA | |
| SCHEMBL4206941 | 0.75 | HTT (0.41) | POLBACSS2KDM4ECNR2CNR1 | |
| SCHEMBL4206940 | 0.73 | CNR2 (0.31) | ACSS2CNR2CNR1 | |
| SCHEMBL3113554 | 0.73 | KCNN4 (0.37) | ACSS2KCNN4LPAR1BCDIN3DBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7179801-B2 | Cephem compounds | ASTELLAS PHARMA INC. (JP) | 2007-02-20 | — | — | US | disclosed |
| EP-1392704-B1 | CEPHEM COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2006-02-22 | — | — | EP | disclosed |
| US-20040248875-A1 | Cephem compounds | ASTELLAS PHARMA INC. (JP) | 2004-12-09 | — | — | US | disclosed |
| EP-1392704-A1 | CEPHEM COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002090364-A1 | CEPHEM COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248875-A1 | Cephem compounds | CEP170, C1S, SLC7A1 | POLB 3003/4885ACSS2 791/4885CYP11B1 418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.